Identification of MMP28 as a biomarker for the differential diagnosis of idiopathic pulmonary fibrosis

dc.contributor.authorMaldonado, Mariel
dc.contributor.authorBuendía Roldán, Ivette
dc.contributor.authorVicens-Zygmunt, Vanesa
dc.contributor.authorPlanas Cerezales, Lurdes
dc.contributor.authorMolina Molina, María
dc.contributor.authorSelman, Moisés
dc.contributor.authorPardo, Annie
dc.date.accessioned2020-11-24T12:25:19Z
dc.date.available2020-11-24T12:25:19Z
dc.date.issued2018-01-12
dc.date.updated2020-11-11T17:41:17Z
dc.description.abstractBackground and objective: Idiopathic Pulmonary Fibrosis (IPF) is a progressive disease of unknown etiology. The diagnosis is based on the identification of a pattern of usual interstitial pneumonia either by high resolution computed tomography and/or histology. However, a similar pattern can be observed in other fibrotic lung disorders, and precise diagnosis remains challenging. Studies on biomarkers contributing to the differential diagnosis are scanty, and still in an exploratory phase. Our aim was to evaluate matrix metalloproteinase (MMP)-28, which has been implicated in abnormal wound healing, as a biomarker for distinguishing IPF from fibrotic non-IPF patients. Methods: The cell localization of MMP28 in lungs was examined by immunohistochemistry and its serum concentration was measured by ELISA in two different populations. The derivation cohort included 82 IPF and 69 fibrotic non-IPF patients. The validation cohort involved 42 IPF and 41 fibrotic non-IPF patients. Results: MMP28 was detected mainly in IPF lungs and localized in epithelial cells. In both cohorts, serum concentrations of MMP28 were significantly higher in IPF versus non-IPF (mostly with lung fibrosis associated to autoimmune diseases and chronic hypersensitivity pneumonitis) and healthy controls (ANOVA, p<0.0001). The AUC of the derivation cohort was 0.718 (95% CI, 0.635-0.800). With a cutoff point of 4.5 ng/mL, OR was 5.32 (95%CI, 2.55-11.46), and sensitivity and specificity of 70.9% and 69% respectively. The AUC of the validation cohort was 0.690 (95%CI, 0.581-0.798), OR 4.57 (95%CI, 1.76-12.04), and sensitivity and specificity of 69.6% and 66.7%. Interestingly, we found that IPF patients with definite UIP pattern on HRCT showed higher serum concentrations of MMP28 than non-IPF patients with the same pattern (7.8 +/- 4.4 versus 4.9 +/- 4.4; p = 0.04). By contrast, no differences were observed when IPF with possible UIP-pattern were compared (4.7 +/- 3.2 versus 3.9 +/- 3.0; p = 0.43). Conclusion These findings indicate that MMP28 might be a useful biomarker to improve the diagnostic certainty of IPF.
dc.format.extent11 p.
dc.format.mimetypeapplication/pdf
dc.identifier.pmid30208119
dc.identifier.urihttps://hdl.handle.net/2445/172273
dc.language.isoeng
dc.publisherPublic Library of Science (PLoS)
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1371/journal.pone.0203779
dc.relation.ispartofPLoS One, 2018, vol. 13, num. 9, p. e0203779
dc.relation.urihttps://doi.org/10.1371/journal.pone.0203779
dc.rightscc by (c) Maldonado et al., 2018
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationFibrosi pulmonar
dc.subject.classificationMarcadors bioquímics
dc.subject.otherPulmonary fibrosis
dc.subject.otherBiochemical markers
dc.titleIdentification of MMP28 as a biomarker for the differential diagnosis of idiopathic pulmonary fibrosis
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
MaldonadoM.pdf
Mida:
6.09 MB
Format:
Adobe Portable Document Format